Exosens EBIT

The latest EBIT for EXENS.PA is $180M as of June 2026. That compares with $90M in the prior-year period — up 98.0% year over year. That is below the Technology sector average of $110T. Investors often review this figure alongside Exosens's historical trend and sector peers before judging valuation or financial health.

Over the past year, EXENS.PA's EBIT moved from $90M to $180M — a 98.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Exosens's operating scale or balance-sheet position.

Against Technology companies, EXENS.PA currently prints $180M for EBIT, while the sector average sits near $110T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Exosens's growth, margins, and balance sheet.

A EBIT figure of $180M for EXENS.PA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Technology average is about $110T. Explore the charts below for those layers of context.

After noting EXENS.PA's EBIT ($180M), review year-over-year change from $90M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.